A new study, published in the peer-reviewed journal AI in Precision Oncology, examines the ability of large language models ...
Researchers from the University of Chicago Medicine Comprehensive Cancer Center have demonstrated the potential of a novel ...
The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...
Tislelizumab plus chemotherapy received FDA approval as a frontline therapy for individuals with unresectable or metastatic ...
Hosted on MSN1mon
Phase III trial shows new treatment boosts cure rate for most common form of breast cancerPD L1 is a protein known to reduce an immune cell's anti-cancer activity, and nivolumab works by blocking the receptor where PD L1 could bind to an immune cell, so preserving its anti-cancer activity.
The global PD-L1 biomarker testing market is on a strong growth trajectory, rising from USD 777.2 million in 2025 to USD 1,690.8 million by 2035, at a CAGR of 8.1% during the forecast period.PD-L1 ...
A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.
Ilab Co. Ltd. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer. Copyright ©2025. All ...
Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.
A new study published in AI in Precision Oncology examines the ability of large language models (LLMs) to rapidly extract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback